ClinicalTrials.gg
CompletedNCT04500067Updated Oct 14, 2020

Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment

A Phase 3 interventional study of IVIG in Covid19 and Pneumonia, sponsored by Biopharma Plasma LLC. Completed at 9 sites in Ukraine. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-14.

Sponsored by Biopharma Plasma LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in COVID-19 with a site in Ukraine — 1 open to participants now, 1 under way, 1 of them phase 3. COVID-19 · Ukraine.

Enrollment
33rd of 39
76 · median 285
Started
2020
with 14 others
Phase 3
19 of 45
1 open now
Registered
6th of 45
by date
Lead sponsor
1 of 45
Biopharma Plasma LLC

Among the 45 studies in COVID-19 with a site in Ukraine, this one is the 33rd largest by enrollment of the 39 interventional ones that give a count, is one of 15 that started in 2020, is one of 19 in phase 3, and was the 6th registered.

COVID-19

7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 45 studies in COVID-19 with a site in Ukraine is open now. Recruiting first, the newest first:

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in COVID-19 with a site in Ukraine, or all of them as a file.
02

Study summary

Pneumonia caused by coronavirus infection COVID-19 is characterized by a combination of several dangerous factors that consistently worsen the patient's condition: viral lung damage early in the disease; a sharp increase in inflammation on the background of an unbalanced immune response ("cytokine storm"); joining a bacterial infection.

The condition of patients deteriorates significantly mostly at cytokine storm development. The damaging of a large volume of lung tissue leads to develops of respiratory failure, respiratory distress syndrome, or shock. Ventilatory support becomes ineffective and patients die.

There are reports of the effectiveness of Human Normal Immunoglobulin for Intravenous Administration (IVIG) high doses when used as part of complex therapy in patients with pneumonia caused by coronavirus COVID-19. In particular, IVIG has a positive effect on survival rates, overall disease course, duration of stay in the intensive care unit, and ventilatory support duration.

The probable mechanism of action of high-dose IVIG therapy is considered to be a regulatory effect on the immune system. Similar is the known and confirmed effectiveness of IVIG for autoimmune diseases (Kavasaky disease, Guillain Barre syndrome, Chronic inflammatory demyelinating polyradiculoneuropathy, Multifocal motor neuropathy).

This trial to assesses the Efficacy of IVIG (medication trade name - Bioven, manufactured by Biopharma Plasma LLC) in the High Immunomodulatory Dose in Complex Treatment of Severe Pneumonia Caused by COVID-19 / SARS-CoV-2

Read the detailed description

The screening stage:

The patient or his legal representative must sign an informed consent. After signing the informed consent, the screening tests\&procedures are performed and the compliance with the inclusion / non-inclusion criteria is assessed.

For patients who have been screened and meet the inclusion criteria and do not fall under the exclusion criteria, a blinded randomization procedure is provided.

Randomization is performed by the IVRS method, according to the blinded-block patient's randomization table.

The clinical stage of the trial:

Begins after patient randomization. At the clinical stage, among other things, provides:

  • Determination of the individual dose of the study drug (in the study group)
  • Administration of the drug (in the study group)
  • Registration of adverse events
  • registration of information about taking antiviral drugs for the treatment of COVID-19;
  • registration of information on symptomatic therapy and administration of drugs for the treatment of comorbidities;
  • measurement of vital signs (blood pressure, heart rate, respiratory rate, body temperature);
  • Determination of SPO2 level
  • Determining the need for ventilation
  • Determining the need for intensive care
  • Assessment of compliance with the exclusion criteria

Patients in the Control Group will receive therapy recommended by the COVID-19 coronavirus infection treatment protocol, depending on the severity of their condition according to the prescribing list, which will not include immunoglobulin preparations.

Patients of the Study Group (IVIG) receive high-dose therapy with the study drug (Bioven, 10% solution for infusions produced by Biopharma Plasma LLC, Ukraine). The dose is calculated by body weight. Patients will also receive therapy recommended by the COVID-19 coronavirus infection treatment protocol, depending on the severity of their condition according to the prescribing list.

Bioven administered intravenously, at an initial rate of 0.5 - 1.0 ml/kg body weight/hour for 30 minutes. In the absence of any undesirable side effects, the rate of administration can be gradually increased (recommended increase by 0.5 - 1.5 ml/kg body weight/hour every 10 minutes). According to results previously accomplished clinical studies, the maximum rate of Bioven administration is up to 8.5 ml/kg body weight/hour.

Observation and completion stage:

Begins and continues from the last administration of the study drug until the discharge of the patient from the hospital, but not less than 28 days from the confirmation of the diagnosis of pneumonia caused by coronavirus infection COVID-19.

The following procedures are provided at the stage:

  • registration of information about taking antiviral drugs for the treatment of COVID-19;
  • registration of information on symptomatic therapy and administration of drugs for the treatment of comorbidities;
  • measurement of vital signs (blood pressure, heart rate, respiratory rate, body temperature);
  • determination of SPO2 level
  • registration of the results of the examination of the lungs by computed tomography (or radiography)
  • taking biomaterials for laboratory research:
  • general blood test (erythrocytes, hemoglobin, expanded leukocyte formula, platelets, etc.);
  • general analysis of urine;
  • biochemical analysis of blood;
  • state of the coagulation system
  • determination of inflammatory factors in the dynamics (CRP, ferritin, procalcitonin; TNF-α), IL-1-beta, IL-6, complement component C3 (C3), circulating immune complexes (CIC), etc.),
  • determination of IgG subclasses (G1, G2, G3, G4,);
  • Determining the need for ventilation
  • Determining the need for intensive care
  • Adverse reactions registration
  • Assessment of compliance with the exclusion criteria

The patient's condition is assessed daily till discharge; and by schedule after discharge (if it happen earlier), during 28 days period after diagnosis of severe pneumonia caused by coronavirus infection COVID-19 In case of death of the patient - the date and cause of death are fixed. The results of the study are evaluated by endpoints.

03

Conditions studied

  • Covid19
  • Pneumonia

Keywords

  • Pneumonia
  • COVID-19
  • SARS-CoV-2
  • IVIG
  • Immunoglobulin for Intravenous Administration
  • Bioven
  • Coronavirus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women 18 years of age and older;
  • COVID-19 documentary confirmed by PCR lab test;
  • severe pneumonia caused by COVID-19 according to the criteria below:

      • fever or suspicion of respiratory infection;
      • the number of respiratory movements 30 per 1 min and above;
      • severe respiratory failure or SpO2 \<90% with spontaneous breathing indoors;
      • the presence of foci of inflammation in the lungs according to the results of computed tomography, which is documented.
    • or if any of the conditions listed below have developed on the background of previously diagnosed coronavirus pneumonia:

        • severe respiratory failure required mechanical ventilation (ALV);
        • acute respiratory distress syndrome according to WHO diagnostic criteria (development within one week after the manifestation of disease clinical symptoms or emergence of new ones or deterioration of respiratory syndromes. Chest visualization (lung X-ray, CT or ultrasound); bilateral opacities not fully explaining the gravity of condition or lung collapse or nodules);
        • sepsis according to WHO diagnostic criteria (life-threatening organ dysfunction caused by disturbance of host reaction to suspected or proven infection. The features of organ dysfunction include the following: mental change, labored or shallow breathing, low oxygenation, oliguria or anuria, rapid heart palpitation, weak pulse, cold extremities or low blood pressure, skin blotching or lab-proven coagulopathy, thrombocytopenia, acidosis, high level of lactic acid or hyperbilirubinemia);
        • endotoxic shock according to WHO diagnostic criteria (persisting hypotension despite extensive resuscitation requiring vasoconstrictors for maintaining mean arterial pressure ≥ 65 mmHg and serum lactate level > 2 mmol/l);
  • the signed patient's to participation in the trial;
  • the negative pregnancy test (for female patients of reproductive age), readiness to use reliable methods during the whole duration of the trial.
  • the ability, according to the researcher, to follow all requirements of the research protocol.
  • this study allows you to take into account the results of examinations related to the disease, conducted within 10 days before signing the Informed Consent. Such data are transferred from the primary documentation to the CRF.

Exclusion criteria

Exclusion Criteria:

  • known intolerance to plasma or immunoglobulin drugs;
  • drug allergy or hypersensitization to immunoglobulin drugs;
  • any known counter-indication to immunoglobulin drugs according to the instruction for medical application of the tested drug;
  • pneumonia not associated with COVID-19 infection;
  • pregnancy, lactation period;
  • any impairment of liver function (elevation of serum transaminase levels more than 3 times the );
  • serum creatinine levels more than 2 times the upper limit of normal for a given age and gender;
  • established diagnosis of primary immunodeficiency;
  • verified -infection;
  • immune diseases (blood immune diseases, rheumatic diseases, nephritis, etc.)
  • severe cardiovascular failure (Stage III);
  • mental illness in anamnesis;
  • the need for prescribing medicines or procedures that are incompatible with the administration of the drug within the scope of this study: monoclonal antybodies;
  • known drug addiction;
  • participation in any other clinical trial presently or within the last 30 days.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Study Group (IVIG)

    Patients receive IVIG (trade name - Bioven) with base therapy

    Drug: IVIG

  • No intervention
    Control group

    Patients receive base therapy only

Interventions

  • DrugIVIG

    Patients in the study group receive the drug Bioven, 10% solution for infusions produced by LLC Biopharma Plasma 0,8-1,0 g/kg once a day for 2 days (total course dose - 1.6-2.0 g/kg) as well as base treatment recommended by the protocol of COVID-19 coronavirus infection treatment depending on the severity of their condition according to the prescription sheet.

    Also known as: Human normal immunoglobulin for intravenous administration, Bioven

06

What researchers measure

Primary outcomes

  1. Period duration (in days) to clinical improvement

    Number of days post-onset of severe pneumonia to the moment of normalization at least two from following primary outcomes: O2 saturation with self-breathing, respiratory movements rate with self-breathing, body temperature without antipyretics use, lymphocyte count (targeted levels set in the description each of these primary outcomes)

    Time frame: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 days

  2. O2 saturation (SPO2 percentage), with self-breathing

    The target level of SPO2 percentage - 95% and above with self-breathing, is used as one of the clinical improvement criteria

    Time frame: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 days

  3. Respiratory movements rate (amount per minute), with self-breathing

    The target level of respiratory movements - 28 per minute or less with self-breathing, is used as one of the clinical improvement criteria

    Time frame: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 days

  4. Body temperature without antipyretics use

    Measured in degrees Celsius. Fever absence (body temperature no more 37 degrees Celsius) during at least 24 hours without antipyretics, is used as one of the clinical improvement criteria.

    Time frame: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 days

  5. Lymphocyte count

    The target level 1000 cells / mm3 and above is used as one of the clinical improvement criteria (applicable for patients with lymphocytes count lower 1000 cells / mm3 at screening moment)

    Time frame: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 days

Secondary outcomes

  1. Time from the onset of the disease to discharge, in days

    Period duration (in days)

    Time frame: 28 days

  2. Duration of the need for ventilatory support, in days

    Number of days with ventilatory support

    Time frame: 28 days

  3. Duration of the need for intensive care, in days

    Number of days in the intensive care unit

    Time frame: 28 days

  4. Duration of need for oxygenation in days (SPO2 ≤ 93% with self-breathing)

    Number of days with necessery of oxygenation support

    Time frame: 28 days

  5. The C-reactive protein (CRP) level

    Measuring the analyte concentration in plasma (mg/L)

    Time frame: Day 0 (screening), day 5, day 14, day 28

  6. The tumor necrozis factor alpha (TNF-α) level

    Measuring the analyte concentration in plasma (pg/mL)

    Time frame: Day 0 (screening), day 5, day 14, day 28

  7. The interleukin-1β (IL-1β) level

    Measuring the analyte concentration in plasma (pg/mL)

    Time frame: Day 0 (screening), day 5, day 14, day 28

  8. The interleukin-6 (IL-6) level

    Measuring the analyte concentration in plasma (pg/mL)

    Time frame: Day 0 (screening), day 5, day 14, day 28

  9. The D-dimer level

    Measuring the analyte concentration in plasma (µg FEU/mL)

    Time frame: Day 0 (screening), day 5, day 14, day 28

  10. The Complement (C3 component) level

    Measuring the analyte concentration in plasma (g/L)

    Time frame: Day 0 (screening), day 5, day 14, day 28

  11. The Circulating immune complexes level

    Measuring the analyte concentration in plasma (U/mL)

    Time frame: Day 0 (screening), day 5, day 14, day 28

  12. The ferritin level

    Analyte concentration in plasma (ng/mL)

    Time frame: Day 0 (screening), day 5, day 14, day 28

  13. The procalcitonin level

    Analyte concentration in plasma (ng/mL)

    Time frame: Day 0 (screening), day 5, day 14, day 28

  14. IgG subtypes

    The IgG-subtypes (IgG1-IgG4) concentration in plasma (mg/dL)

    Time frame: Day 0 (screening), day 5, day 14, day 28

  15. Survival assessment for a 28-day follow-up period since the onset of severe pneumonia

    Survivealance estimation

    Time frame: 28 days

Other outcomes

  1. Frequency of side effects

    Number of participants with adverse reactions related by investigational drug as assessed by CTCАЕ v 4.0

    Time frame: 28 days

  2. Frequency of serious side effects

    Number of participants with serious adverse reactions related by investigational drug as assessed by CTCАЕ v 4.0

    Time frame: 28 days

07

Study locations

9 sites
  • Site 08 - "Central City Clinical Hospital of Ivano-Frankivsk City Council"
    Ivano-Frankivs'k, Ivano-Frankivs'k Region 76018, Ukraine
  • Site 02 - "Bila Tserkva City Hospital №3"
    Bila Tserkva, Kyiv Region 09112, Ukraine
  • Site 03 - "Lviv Regional Infectious Diseases Clinical Hospital"
    Lviv, Lviv Region 79010, Ukraine
  • Site 04 - "City Clinical Infectious Diseases Hospital", Odesa
    Odesa, Odesa Region 65021, Ukraine
  • Site 07 - "Ternopil City Municipal Ambulance Hospital"
    Ternopil', Ternopil' Region 46006, Ukraine
  • Site 06 - "Vinnytsia City Clinical Hospital №1"
    Vinnitsia, Vinnitsia Region 21021, Ukraine
  • Site 09 - "Volyn Regional Clinical Hospital"
    Luts'k, Volyn Region 43000, Ukraine
  • Site 01 - "Kyiv City Clinical Hospital №17"
    Kyiv, 03110, Ukraine
  • Site 05 - "Kyiv City Clinical Hospital №4"
    Kyiv, 03110, Ukraine
08

References and documents

Individual participant data

Plan to share: Yes — After completion of the trial, results will be published. Access to parts CSR planned after the release of scientific publications

Supporting information: Clinical study report

Time frame: After trial result publication 3 months later

Access criteria: For specialists in medicine, pharmacy, scientists

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Sep 2020, 4 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 4 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2020
First posted
Aug 5, 2020
StartActual
May 7, 2020
Primary completionActual
Sep 15, 2020
CompletionActual
Sep 15, 2020
Last update
Oct 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04500067
Lead sponsor
Biopharma Plasma LLC
Collaborators
Lviv National Medical University, Vinnitsa National Medical University
Responsible party
Sponsor
First posted
Aug 5, 2020
Start date
May 7, 2020
Primary completion
Sep 15, 2020
Completion
Sep 15, 2020
Last update
Oct 14, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion